{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T22:24:58Z","timestamp":1793744698817,"version":"4.6.1"},"reference-count":52,"publisher":"American Society of Hematology","issue":"7","license":[{"start":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T00:00:00Z","timestamp":1747094400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,8,14]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Despite the success of B-cell maturation antigen (BCMA)\u2013targeting chimeric antigen receptor (CAR) T cells (CAR-Ts) in multiple myeloma, patients with high-risk cytogenetic features continue to relapse most quickly and are in urgent need of additional therapeutic options. Here, we identify CD70, widely recognized as a favorable immunotherapy target in other cancers, as a specifically upregulated cell surface antigen in high-risk myeloma tumors. We use a structure-guided design to define a CD27-based anti-CD70 CAR-T design that outperforms all tested single-chain variable fragment\u2013based CARs, leading to &amp;gt;80-fold improved CAR-T expansion in vivo. Epigenetic analysis via machine learning predicts key transcription factors and transcriptional networks driving CD70 upregulation in high-risk myeloma. Dual-targeting CAR-Ts against either CD70 or BCMA demonstrate a potential strategy to avoid antigen escape\u2013mediated resistance. Together, these findings support the promise of targeting CD70 with optimized CAR-Ts in myeloma as well as future clinical translation of this approach.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/blood.2024025536","type":"journal-article","created":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T16:05:57Z","timestamp":1747152357000},"page":"819-833","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":17,"title":["Targeting high-risk multiple myeloma genotypes with optimized anti-CD70 CAR T cells"],"prefix":"10.1182","volume":"146","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3667-8097","authenticated-orcid":false,"given":"Corynn","family":"Kasap","sequence":"first","affiliation":[{"name":"1Division of Hematology\/Oncology, Department of Medicine, University of California San Francisco, San Francisco, CA"},{"name":"2Department of Laboratory Medicine, University of California San Francisco, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3296-3261","authenticated-orcid":false,"given":"Adila","family":"Izgutdina","sequence":"additional","affiliation":[{"name":"2Department of Laboratory Medicine, University of California San Francisco, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2622-4822","authenticated-orcid":false,"given":"Bonell","family":"Pati\u00f1o-Escobar","sequence":"additional","affiliation":[{"name":"2Department of Laboratory Medicine, University of California San Francisco, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0445-5654","authenticated-orcid":false,"given":"Amrik S.","family":"Kang","sequence":"additional","affiliation":[{"name":"2Department of Laboratory Medicine, University of California San Francisco, San Francisco, CA"},{"name":"3Medical Scientist Training Program, University of California San Francisco, San Francisco, CA"},{"name":"4Department of Medicine, University of California San Francisco, San Francisco, CA"},{"name":"5Gladstone-UCSF Institute of Genomic Immunology, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-3456-8144","authenticated-orcid":false,"given":"Nikhil","family":"Chilakapati","sequence":"additional","affiliation":[{"name":"2Department of Laboratory Medicine, University of California San Francisco, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naomi","family":"Akagi","sequence":"additional","affiliation":[{"name":"2Department of Laboratory Medicine, University of California San Francisco, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-5578-4429","authenticated-orcid":false,"given":"Ananya","family":"Manoj","sequence":"additional","affiliation":[{"name":"2Department of Laboratory Medicine, University of California San Francisco, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-1527-7910","authenticated-orcid":false,"given":"Haley","family":"Johnson","sequence":"additional","affiliation":[{"name":"2Department of Laboratory Medicine, University of California San Francisco, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tasfia","family":"Rashid","sequence":"additional","affiliation":[{"name":"2Department of Laboratory Medicine, University of California San Francisco, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-9635-2519","authenticated-orcid":false,"given":"Juwita","family":"Werner","sequence":"additional","affiliation":[{"name":"6Division of Oncology, Department of Pediatrics, University of California San Francisco, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8158-4949","authenticated-orcid":false,"given":"Abhilash","family":"Barpanda","sequence":"additional","affiliation":[{"name":"2Department of Laboratory Medicine, University of California San Francisco, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huimin","family":"Geng","sequence":"additional","affiliation":[{"name":"2Department of Laboratory Medicine, University of California San Francisco, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Hsiu T.","family":"Lin","sequence":"additional","affiliation":[{"name":"2Department of Laboratory Medicine, University of California San Francisco, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7473-4144","authenticated-orcid":false,"given":"Sham","family":"Rampersaud","sequence":"additional","affiliation":[{"name":"2Department of Laboratory Medicine, University of California San Francisco, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-8504-2842","authenticated-orcid":false,"given":"Daniel","family":"Gil-Al\u00f3s","sequence":"additional","affiliation":[{"name":"2Department of Laboratory Medicine, University of California San Francisco, San Francisco, CA"},{"name":"7Department of Hematology, Hospital 12 de Octubre, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amin","family":"Sobh","sequence":"additional","affiliation":[{"name":"8Division of Hematology\/Oncology, University of Florida Health Cancer Center, Gainesville, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daphn\u00e9","family":"Dup\u00e9r\u00e9-Richer","sequence":"additional","affiliation":[{"name":"8Division of Hematology\/Oncology, University of Florida Health Cancer Center, Gainesville, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8884-2100","authenticated-orcid":false,"given":"Adolfo","family":"Aleman","sequence":"additional","affiliation":[{"name":"9Department of Medicine, Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5524-0245","authenticated-orcid":false,"given":"Gianina","family":"Wicaksono","sequence":"additional","affiliation":[{"name":"2Department of Laboratory Medicine, University of California San Francisco, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. M. Kawehi","family":"Kelii","sequence":"additional","affiliation":[{"name":"2Department of Laboratory Medicine, University of California San Francisco, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7128-5635","authenticated-orcid":false,"given":"Radhika","family":"Dalal","sequence":"additional","affiliation":[{"name":"10Department of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilio","family":"Ramos","sequence":"additional","affiliation":[{"name":"2Department of Laboratory Medicine, University of California San Francisco, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anjanaa","family":"Vijayanarayanan","sequence":"additional","affiliation":[{"name":"2Department of Laboratory Medicine, University of California San Francisco, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiran","family":"Lakhani","sequence":"additional","affiliation":[{"name":"11Department of Hematology and Medical Oncology, Winship Cancer Institute, School of Medicine, Emory University, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Salangsang","sequence":"additional","affiliation":[{"name":"12Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Phojanakong","sequence":"additional","affiliation":[{"name":"12Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7494-1127","authenticated-orcid":false,"given":"Juan Antonio","family":"Camara Serrano","sequence":"additional","affiliation":[{"name":"12Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ons","family":"Zakraoui","sequence":"additional","affiliation":[{"name":"12Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isa","family":"Tariq","sequence":"additional","affiliation":[{"name":"12Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajai","family":"Chari","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Oncology, Department of Medicine, University of California San Francisco, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0196-5456","authenticated-orcid":false,"given":"Alfred","family":"Chung","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Oncology, Department of Medicine, University of California San Francisco, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anupama D.","family":"Kumar","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Oncology, Department of Medicine, University of California San Francisco, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"Thomas G.","family":"Martin","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Oncology, Department of Medicine, University of California San Francisco, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Wolf","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Oncology, Department of Medicine, University of California San Francisco, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandy W.","family":"Wong","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Oncology, Department of Medicine, University of California San Francisco, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Steri","sequence":"additional","affiliation":[{"name":"12Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mala","family":"Shanmugam","sequence":"additional","affiliation":[{"name":"11Department of Hematology and Medical Oncology, Winship Cancer Institute, School of Medicine, Emory University, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9436-8815","authenticated-orcid":false,"given":"Lawrence H.","family":"Boise","sequence":"additional","affiliation":[{"name":"11Department of Hematology and Medical Oncology, Winship Cancer Institute, School of Medicine, Emory University, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanja","family":"Kortemme","sequence":"additional","affiliation":[{"name":"10Department of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, CA"},{"name":"16Chan Zuckerberg Biohub San Francisco, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samir","family":"Parekh","sequence":"additional","affiliation":[{"name":"9Department of Medicine, Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY"},{"name":"13Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY"},{"name":"14Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY"},{"name":"15Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7032-4623","authenticated-orcid":false,"given":"Elliot","family":"Stieglitz","sequence":"additional","affiliation":[{"name":"6Division of Oncology, Department of Pediatrics, University of California San Francisco, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3942-1369","authenticated-orcid":false,"given":"Jonathan D.","family":"Licht","sequence":"additional","affiliation":[{"name":"8Division of Hematology\/Oncology, University of Florida Health Cancer Center, Gainesville, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William J.","family":"Karlon","sequence":"additional","affiliation":[{"name":"2Department of Laboratory Medicine, University of California San Francisco, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9810-3566","authenticated-orcid":false,"given":"Benjamin G.","family":"Barwick","sequence":"additional","affiliation":[{"name":"11Department of Hematology and Medical Oncology, Winship Cancer Institute, School of Medicine, Emory University, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7465-6964","authenticated-orcid":false,"given":"Arun P.","family":"Wiita","sequence":"additional","affiliation":[{"name":"2Department of Laboratory Medicine, University of California San Francisco, San Francisco, CA"},{"name":"10Department of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, CA"},{"name":"12Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA"},{"name":"16Chan Zuckerberg Biohub San Francisco, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"27","key":"2025081411221736200_bib1","doi-asserted-by":"crossref","first-page":"4416","DOI":"10.1200\/JCO.23.00512","article-title":"Chimeric antigen receptor T-cell and bispecific antibody therapy in multiple myeloma: moving into the future","volume":"41","author":"Holstein","year":"2023","journal-title":"J Clin Oncol"},{"issue":"1","key":"2025081411221736200_bib2","first-page":"340","article-title":"Current use of CAR T cells to treat multiple myeloma","volume":"2023","author":"Firestone","year":"2023","journal-title":"Hematol Am Soc Hematol Educ Program 2023"},{"issue":"11","key":"2025081411221736200_bib3","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1200\/JCO.22.01365","article-title":"Idecabtagene vicleucel for relapsed\/refractory multiple myeloma: real-world experience from the myeloma CAR T consortium","volume":"41","author":"Hansen","year":"2023","journal-title":"J Clin Oncol"},{"issue":"6","key":"2025081411221736200_bib4","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1200\/JCO.22.00842","article-title":"Ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed\/refractory multiple myeloma: CARTITUDE-1 2-year follow-up","volume":"41","author":"Martin","year":"2023","journal-title":"J Clin Oncol"},{"issue":"7","key":"2025081411221736200_bib5","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1182\/blood.2022017848","article-title":"Interventions and outcomes of patients with multiple myeloma receiving salvage therapy after BCMA-directed CAR T therapy","volume":"141","author":"Van Oekelen","year":"2023","journal-title":"Blood"},{"issue":"6","key":"2025081411221736200_bib6","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1172\/JCI126397","article-title":"B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma","volume":"129","author":"Cohen","year":"2019","journal-title":"J Clin Invest"},{"issue":"9","key":"2025081411221736200_bib7","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1038\/s41591-023-02491-5","article-title":"Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma","volume":"29","author":"Lee","year":"2023","journal-title":"Nat Med"},{"issue":"485","key":"2025081411221736200_bib8","doi-asserted-by":"crossref","first-page":"eaau7746","DOI":"10.1126\/scitranslmed.aau7746","article-title":"GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells","volume":"11","author":"Smith","year":"2019","journal-title":"Sci Transl Med"},{"issue":"13","key":"2025081411221736200_bib9","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1056\/NEJMoa2209900","article-title":"GPRC5D-targeted CAR T cells for myeloma","volume":"387","author":"Mailankody","year":"2022","journal-title":"N Engl J Med"},{"key":"2025081411221736200_bib10","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.3390\/vaccines11111721","article-title":"CAR-T-cell therapy in multiple myeloma: B-cell maturation antigen (BCMA) and beyond","volume":"11","author":"Mishra","year":"2023","journal-title":"Vaccines"},{"issue":"6472","key":"2025081411221736200_bib11","doi-asserted-by":"crossref","first-page":"eaax9198","DOI":"10.1126\/science.aax9198","article-title":"A genome-wide transcriptomic analysis of protein-coding genes in human blood cells","volume":"366","author":"Uhlen","year":"2019","journal-title":"Science"},{"key":"2025081411221736200_bib12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pharmthera.2015.07.007","article-title":"CD70: an emerging target in cancer immunotherapy","volume":"155","author":"Jacobs","year":"2015","journal-title":"Pharmacol Ther"},{"issue":"10","key":"2025081411221736200_bib13","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.3390\/cancers11101611","article-title":"Screening a broad range of solid and haematological tumour types for CD70 expression using a uniform IHC methodology as potential patient stratification method","volume":"11","author":"Flieswasser","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"1","key":"2025081411221736200_bib14","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s13046-021-02215-y","article-title":"The CD70-CD27 axis in oncology: the new kids on the block","volume":"41","author":"Flieswasser","year":"2022","journal-title":"J Exp Clin Cancer Res"},{"issue":"3","key":"2025081411221736200_bib15","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1093\/intimm\/6.3.477","article-title":"CD70 represents the human ligand for CD27","volume":"6","author":"Hintzen","year":"1994","journal-title":"Int Immunol"},{"issue":"9","key":"2025081411221736200_bib16","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1038\/s41591-020-0910-8","article-title":"Targeting CD70 with cusatuzumab eliminates acute myeloid leukemia stem cells in patients treated with hypomethylating agents","volume":"26","author":"Riether","year":"2020","journal-title":"Nat Med"},{"issue":"4","key":"2025081411221736200_bib17","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.ccell.2017.09.004","article-title":"Integrating proteomics and transcriptomics for systematic combinatorial chimeric antigen receptor therapy of AML","volume":"32","author":"Perna","year":"2017","journal-title":"Cancer Cell"},{"issue":"23","key":"2025081411221736200_bib18","doi-asserted-by":"crossref","first-page":"7763","DOI":"10.1158\/1078-0432.CCR-08-0493","article-title":"Preclinical characterization of SGN-70, a humanized antibody directed against CD70","volume":"14","author":"McEarchern","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"14","key":"2025081411221736200_bib19","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1158\/0008-5472.CAN-21-2931","article-title":"Preclinical development and evaluation of allogeneic CAR T cells targeting CD70 for the treatment of renal cell carcinoma","volume":"82","author":"Panowski","year":"2022","journal-title":"Cancer Res"},{"issue":"2","key":"2025081411221736200_bib20","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.ccell.2023.01.007","article-title":"CD70 is a therapeutic target upregulated in EMT-associated EGFR tyrosine kinase inhibitor resistance","volume":"41","author":"Nilsson","year":"2023","journal-title":"Cancer Cell"},{"issue":"298","key":"2025081411221736200_bib21","doi-asserted-by":"crossref","first-page":"298ra119","DOI":"10.1126\/scitranslmed.aab1740","article-title":"Tyrosine kinase inhibitor-induced CD70 expression mediates drug resistance in leukemia stem cells by activating Wnt signaling","volume":"7","author":"Riether","year":"2015","journal-title":"Sci Transl Med"},{"issue":"5","key":"2025081411221736200_bib22","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.ccell.2022.04.001","article-title":"Non-cleavable hinge enhances avidity and expansion of CAR-T cells for acute myeloid leukemia","volume":"40","author":"Leick","year":"2022","journal-title":"Cancer Cell"},{"issue":"4","key":"2025081411221736200_bib23","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1182\/blood.2020008221","article-title":"CD70-specific CAR T cells have potent activity against acute myeloid leukemia without HSC toxicity","volume":"138","author":"Sauer","year":"2021","journal-title":"Blood"},{"issue":"1","key":"2025081411221736200_bib24","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/S1470-2045(24)00508-4","article-title":"Safety and activity of CTX130, a CD70-targeted allogeneic CRISPR-Cas9-engineered CAR T-cell therapy, in patients with relapsed or refractory T-cell malignancies (COBALT-LYM): a single-arm, open-label, phase 1, dose-escalation study","volume":"26","author":"Iyer","year":"2025","journal-title":"Lancet Oncol"},{"issue":"7","key":"2025081411221736200_bib25","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1158\/2159-8290.CD-24-0102","article-title":"CD70-targeted allogeneic CAR T-cell therapy for advanced clear cell renal cell carcinoma","volume":"14","author":"Pal","year":"2024","journal-title":"Cancer Discov"},{"issue":"2","key":"2025081411221736200_bib26","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1158\/2326-6066.CIR-14-0127","article-title":"The nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity","volume":"3","author":"Hudecek","year":"2015","journal-title":"Cancer Immunol Res"},{"issue":"9","key":"2025081411221736200_bib27","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1038\/s41588-024-01853-0","article-title":"Comprehensive molecular profiling of multiple myeloma identifies refined copy number and expression subtypes","volume":"56","author":"Skerget","year":"2024","journal-title":"Nat Genet"},{"issue":"1","key":"2025081411221736200_bib28","doi-asserted-by":"crossref","first-page":"4121","DOI":"10.1038\/s41467-022-31810-6","article-title":"The surfaceome of multiple myeloma cells suggests potential immunotherapeutic strategies and protein markers of drug resistance","volume":"13","author":"Ferguson","year":"2022","journal-title":"Nat Commun"},{"issue":"16","key":"2025081411221736200_bib29","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1182\/blood.2021015161","article-title":"Unbiased cell surface proteomics identifies SEMA4A as an effective immunotherapy target for myeloma","volume":"139","author":"Anderson","year":"2022","journal-title":"Blood"},{"issue":"26","key":"2025081411221736200_bib30","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","article-title":"Revised International Staging System for multiple myeloma: a report from International Myeloma Working Group","volume":"33","author":"Palumbo","year":"2015","journal-title":"J Clin Oncol"},{"issue":"11","key":"2025081411221736200_bib31","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1182\/blood.2022017863","article-title":"Biallelic deletion of 1p32 defines ultra-high-risk myeloma, but monoallelic del(1p32) remains a strong prognostic factor","volume":"141","author":"Schavgoulidze","year":"2023","journal-title":"Blood"},{"issue":"6","key":"2025081411221736200_bib32","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1182\/blood-2005-11-013458","article-title":"The molecular classification of multiple myeloma","volume":"108","author":"Zhan","year":"2006","journal-title":"Blood"},{"issue":"16","key":"2025081411221736200_bib33","doi-asserted-by":"crossref","first-page":"4304","DOI":"10.1182\/blood-2010-04-278218","article-title":"T cells redirected against CD70 for the immunotherapy of CD70-positive malignancies","volume":"117","author":"Shaffer","year":"2011","journal-title":"Blood"},{"key":"2025081411221736200_bib34","doi-asserted-by":"crossref","first-page":"26979","DOI":"10.1038\/srep26979","article-title":"The proteasome deubiquitinase inhibitor VLX1570 shows selectivity for ubiquitin-specific protease-14 and induces apoptosis of multiple myeloma cells [published correction appears in Sci Rep. 2016:6:30667]","volume":"6","author":"Wang","year":"2016","journal-title":"Sci Rep"},{"issue":"7","key":"2025081411221736200_bib35","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.jcyt.2024.02.024","article-title":"Alternative target recognition elements for chimeric antigen receptor (CAR) T cells: beyond standard antibody fragments","volume":"26","author":"Nix","year":"2024","journal-title":"Cytotherapy"},{"issue":"9","key":"2025081411221736200_bib36","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1158\/1078-0432.CCR-16-1421","article-title":"Preclinical evaluation of chimeric antigen receptors targeting CD70-expressing cancers","volume":"23","author":"Wang","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"4","key":"2025081411221736200_bib37","doi-asserted-by":"crossref","first-page":"101102","DOI":"10.1016\/j.jbc.2021.101102","article-title":"Structural delineation and phase-dependent activation of the costimulatory CD27:CD70 complex","volume":"297","author":"Liu","year":"2021","journal-title":"J Biol Chem"},{"issue":"10","key":"2025081411221736200_bib38","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1007\/s00262-023-03475-7","article-title":"Revealing the impact of CD70 expression on the manufacture and functions of CAR-70 T-cells based on single-cell transcriptomics","volume":"72","author":"Cheng","year":"2023","journal-title":"Cancer Immunol Immunother"},{"issue":"7","key":"2025081411221736200_bib39","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/s41592-020-0848-2","article-title":"Macromolecular modeling and design in Rosetta: recent methods and frameworks","volume":"17","author":"Leman","year":"2020","journal-title":"Nat Methods"},{"key":"2025081411221736200_bib40","article-title":"CD70 targeted chimeric antigen receptor (CAR) T cells and uses thereof","author":"Maus","year":"15, 2022","journal-title":"US patent 2020US20220411478A1"},{"issue":"5","key":"2025081411221736200_bib41","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41591-018-0010-1","article-title":"Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia [published correction appears in Nat Med. 2021;27(3):561]","volume":"24","author":"Fraietta","year":"2018","journal-title":"Nat Med"},{"issue":"303","key":"2025081411221736200_bib42","doi-asserted-by":"crossref","first-page":"303ra139","DOI":"10.1126\/scitranslmed.aac5415","article-title":"Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia","volume":"7","author":"Porter","year":"2015","journal-title":"Sci Transl Med"},{"issue":"7925","key":"2025081411221736200_bib43","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1038\/s41586-022-05126-w","article-title":"RASA2 ablation in T cells boosts antigen sensitivity and long-term function","volume":"609","author":"Carnevale","year":"2022","journal-title":"Nature"},{"issue":"9","key":"2025081411221736200_bib44","doi-asserted-by":"crossref","first-page":"e1004566","DOI":"10.1371\/journal.pgen.1004566","article-title":"Histone methyltransferase MMSET\/NSD2 alters EZH2 binding and reprograms the myeloma epigenome through global and focal changes in H3K36 and H3K27 methylation","volume":"10","author":"Popovic","year":"2014","journal-title":"PLoS Genet"},{"issue":"3","key":"2025081411221736200_bib45","doi-asserted-by":"crossref","first-page":"100025","DOI":"10.1016\/j.bneo.2024.100025","article-title":"Functional multi-omics reveals genetic and pharmacologic regulation of surface CD38 in multiple myeloma","volume":"1","author":"Choudhry","year":"2024","journal-title":"Blood Neoplasia"},{"issue":"19","key":"2025081411221736200_bib46","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1182\/blood-2017-09-808063","article-title":"Active enhancer and chromatin accessibility landscapes chart the regulatory network of primary multiple myeloma","volume":"131","author":"Jin","year":"2018","journal-title":"Blood"},{"issue":"5","key":"2025081411221736200_bib47","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/ni1454","article-title":"Pax5: the guardian of B cell identity and function","volume":"8","author":"Cobaleda","year":"2007","journal-title":"Nat Immunol"},{"issue":"26","key":"2025081411221736200_bib48","doi-asserted-by":"crossref","first-page":"3604","DOI":"10.1182\/blood.2020007899","article-title":"Venetoclax sensitivity in multiple myeloma is associated with B-cell gene expression","volume":"137","author":"Gupta","year":"2021","journal-title":"Blood"},{"issue":"2","key":"2025081411221736200_bib49","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1182\/blood.2023020621","article-title":"CD19\/CD22 targeting with cotransduced CAR T cells to prevent antigen-negative relapse after CAR T-cell therapy for B-cell ALL","volume":"143","author":"Ghorashian","year":"2024","journal-title":"Blood"},{"issue":"2","key":"2025081411221736200_bib50","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1158\/2643-3230.BCD-20-0020","article-title":"Defining an optimal dual-targeted CAR T-cell therapy approach simultaneously targeting BCMA and GPRC5D to prevent BCMA escape-driven relapse in multiple myeloma","volume":"1","author":"Fern\u00e1ndez de Larrea","year":"2020","journal-title":"Blood Cancer Discov"},{"issue":"25","key":"2025081411221736200_bib51","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1200\/JCO.22.00622","article-title":"Modern myeloma therapy + sustained minimal residual disease-negative = (functional) cure","volume":"40","author":"Landgren","year":"2022","journal-title":"J Clin Oncol"},{"issue":"23","key":"2025081411221736200_bib52","doi-asserted-by":"crossref","first-page":"5290","DOI":"10.1182\/bloodadvances.2021004603","article-title":"Humoral immune reconstitution after anti-BCMA CAR T-cell therapy in relapsed\/refractory multiple myeloma","volume":"5","author":"Wang","year":"2021","journal-title":"Blood Adv"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/146\/7\/819\/2405877\/blood_bld-2024-025536-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/146\/7\/819\/2405877\/blood_bld-2024-025536-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T15:22:30Z","timestamp":1755184950000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/146\/7\/819\/537241\/Targeting-high-risk-multiple-myeloma-genotypes"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,14]]},"references-count":52,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,8,14]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2024025536","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2024.02.24.581875","asserted-by":"object"}]},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,8,14]]},"published":{"date-parts":[[2025,8,14]]}}}